Sol-gel and mayne pharma announce the purchase of epsolay® and twyneo® in the u.s.

Sol-gel to receive $16 million during 2025 cash runway is expected to extend into the first quarter of 2027; company expects to have sufficient cash to complete its phase iii clinical trial sgt-610 phase iii clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved sol-gel now estimates the u.s. market potential for sgt-610 to be between $400 to $500 million annually sgt-210 phase 1b trial in darier patients is ongoing; 50% of the patients have already completed the trial ness ziona, israel, april 17, 2025 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of mayne pharma group limited (asx: myx) (mayne pharma) for the sale and exclusive license of the u.s. rights to epsolay and twyneo.
SLGL Ratings Summary
SLGL Quant Ranking